Evidence map›Paper›PMID 34832380›Full record

ArticleMaterials (Basel, Switzerland)2021

Selected Derivatives of Erythromycin B-

Pranab K Bhadra, Rachael N Magwaza, Niroshini Nirmalan, Sally Freeman, Jill Barber, Biljana Arsic

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Pranab K BhadraDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK.
Rachael N MagwazaDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK.
Niroshini NirmalanSchool of Science, Engineering & Environment, University of Salford, Manchester M5 4WT, UK.
Sally FreemanDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK.ORCID 0000-0002-3831-9151
Jill BarberDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK.ORCID 0000-0002-5424-0291
Biljana ArsicDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Oxford Road, Manchester M13 9PT, UK.ORCID 0000-0002-1248-5864
University of Manchester · GBUniversity of Nis · RSUniversity of Salford · GB

Funding

Ministry of Education, Science and Technological Development of Republic of Serbia 451-03-9/2021-14/200124Wellcome Trust 107881
6 · The paper itself

Abstract

Erythromycin A is an established anti-bacterial agent against Gram-positive bacteria, but it is unstable to acid. This led to an evaluation of erythromycin B and its derivatives because these have improved acid stability. These compounds were investigated for their anti-malarial activities, by their

Indexed as

anti-malarial activityconformational searcherythromycin B derivativesinteractionsmolecular docking

Identifiers

PMID34832380
PMCPMC8618316
OpenAlexW3213968808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.